IBSA Pharma Inc. Issues Voluntary Nationwide Recall of Select Lots of TIROSINT®-SOL (levothyroxine sodium) Oral Solution Due to Subpotency. Click for details
IMPORTANT SAFETY INFORMATION for TIROSINT-SOL (levothyroxine sodium) ORAL SOLUTION
WARNING: NOT FOR THE TREATMENT OF OBESITY OR FOR WEIGHT LOSS
Thyroid hormones, including TIROSINT-SOL, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss.
In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction.
Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
Warnings and Precautions
Limitations of Use
Adverse reactions associated with TIROSINT-SOL are primarily those of hyperthyroidism due to therapeutic overdosage including: arrhythmias, myocardial infarction, dyspnea, muscle spasm, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash
For more information, visit www.ibsagroup.com/media
*For Full Prescribing Information, visit www.TirosintSOL.com